BioSpaceOriginal article
BMS’ Phase 3 win for lung drug clouded by high-dose miss
Phase 3MixedLPA1 antagonistNegative
AI Analysis
Summary
BMS' Phase 3 trial for an LPA1 antagonist in idiopathic pulmonary fibrosis showed a low-dose efficacy signal but failed at the higher dose, with a recent patient death complicating the regulatory pathway.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Low-dose demonstrated efficacy, high-dose failed to meet primary endpoint
Importance:7/10
Sentiment:
-0.30
Phase 3LPA1 antagonistidiopathic pulmonary fibrosisregulatory riskpatient safety
Related Companies
Read the original article
Published by BioSpace on October 12, 2026 3:04 PM